Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Fairbanks Capital Management Inc.

Fairbanks Capital Management Inc. reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,934 shares of the specialty pharmaceutical company’s stock after selling 567 shares during the quarter. Jazz Pharmaceuticals comprises approximately 2.2% of Fairbanks Capital Management Inc.’s portfolio, making the stock its 17th biggest position. Fairbanks Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $3,123,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Rise Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the period. Cape Investment Advisory Inc. grew its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares during the period. Assetmark Inc. grew its holdings in shares of Jazz Pharmaceuticals by 37.1% during the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Newbridge Financial Services Group Inc. lifted its position in Jazz Pharmaceuticals by 254.5% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock worth $58,000 after acquiring an additional 336 shares in the last quarter. Finally, Covestor Ltd lifted its position in Jazz Pharmaceuticals by 107.4% during the 1st quarter. Covestor Ltd now owns 618 shares of the specialty pharmaceutical company’s stock worth $74,000 after acquiring an additional 320 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on JAZZ shares. Morgan Stanley cut their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. UBS Group decreased their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research note on Tuesday, July 2nd. HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, May 3rd. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $185.86.

Jazz Pharmaceuticals Trading Up 1.0 %

Shares of NASDAQ JAZZ traded up $1.16 during mid-day trading on Tuesday, hitting $112.27. 695,507 shares of the company traded hands, compared to its average volume of 675,565. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $146.70. The stock has a market capitalization of $7.08 billion, a price-to-earnings ratio of 23.15, a PEG ratio of 1.72 and a beta of 0.58. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The business has a 50 day moving average of $107.37 and a two-hundred day moving average of $114.18.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 15.32 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.